AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K

a9173m

FORM 6-K


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or...

Related Keywords

United Kingdom ,China ,Japan ,Cambridge ,Cambridgeshire ,United States ,Houston ,Texas ,Washington ,America ,Astrazeneca Calquence ,Susan Galbraith ,Adrian Kemp ,Liud Acalabrutinib ,Michael Wang ,Md Anderson Cancer Center ,Lymphoma Research Foundation ,Commission File Number ,Investor Relations Team ,Gracell Biotechnologies Inc ,Mantle Cell Lymphoma Program Of Excellence ,Astrazeneca ,National Organization For Rare Disorders ,Nasdaq ,Company Secretary ,Health Database Study ,Securities Exchange ,Company On Social Media Astrazeneca ,Foreign Issuer ,Securities Exchange Act ,File Number ,Crick Avenue ,Regulationst Rule ,Puddin Clarke Endowed Professor ,Mantle Cell Lymphoma Program ,Clinical Trials ,Cancer Center ,Executive Vice President ,South America ,Rare Diseases ,Social Media ,Mantle Cell ,Accessed April ,Combination With Acalabrutinib ,Subjects With Previously Untreated ,Increased Risk ,Immunocompromised Individuals Despite Receipt ,Retrospective Health Database Study ,Markets ,